Cargando…

Research Progress of Pharmacogenomics in Drug-Induced Liver Injury

Background: Drug-induced liver injury (DILI) is a common and serious adverse drug reaction with insufficient clinical diagnostic strategies and treatment methods. The only clinically well-received method is the Roussel UCLAF Causality Assessment Method scale, which can be applied to both individuals...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shao, Qihui, Mao, Xinyu, Zhou, Zhixuan, Huai, Cong, Li, Zhiling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8450320/ https://www.ncbi.nlm.nih.gov/pubmed/34552491 http://dx.doi.org/10.3389/fphar.2021.735260

Ejemplares similares

Liver expression quantitative trait loci: a foundation for pharmacogenomic research
por: Glubb, Dylan M., et al.
Publicado: (2012)

Pharmacogenomics and adverse drug reactions in children
por: Rieder, Michael J., et al.
Publicado: (2014)

The pharmacogenomics of carbamazepine-induced cutaneous adverse drug reaction in the South of Vietnam
por: Nguyen, Ai-Hoc, et al.
Publicado: (2023)

Editorial: Brief research reports in pharmacogenetics and pharmacogenomics: 2022
por: Sessa, Francesco, et al.
Publicado: (2023)

Research progress on pleiotropic neuroprotective drugs for traumatic brain injury
por: Zhao, Qinghui, et al.
Publicado: (2023)

Editorial: Big Data, Pharmacogenomics and Real-World Research in Pharmacology
por: Wei, James Cheng-Chung, et al.
Publicado: (2020)

Pharmacogenomics of NSAID-Induced Upper Gastrointestinal Toxicity
por: McEvoy, L., et al.
Publicado: (2021)

Editorial: NSAIDs Pharmacogenomics
por: Agúndez, José A. G., et al.
Publicado: (2021)

Antifungal Drugs and Drug-Induced Liver Injury: A Real-World Study Leveraging the FDA Adverse Event Reporting System Database
por: Zhou, Zhi-Xuan, et al.
Publicado: (2022)

Individualized medication based on pharmacogenomics and treatment progress in children with IgAV nephritis
por: Yang, Xuerong, et al.
Publicado: (2022)

Pathway-Targeted Pharmacogenomics of CYP1A2 in Human Liver
por: Klein, Kathrin, et al.
Publicado: (2010)

Editorial: Improving cancer chemotherapy through pharmacogenomics: a research topic
por: Quiñones, Luis A., et al.
Publicado: (2015)

Pharmacogenomics: What is Next?
por: di Iulio, Julia, et al.
Publicado: (2012)

Pharmacogenomics in oncology care
por: Filipski, Kelly K., et al.
Publicado: (2014)

Editorial: Pharmacogenomics and ethnicity: Prevalence and clinical significance of pharmacogenomic biomarkers in indigenous and other populations
por: Patrinos, George P., et al.
Publicado: (2023)

Research Progress and Prospect of Nanoplatforms for Treatment of Oral Cancer
por: Zhao, Zhilong, et al.
Publicado: (2020)

A Survey of Pharmacogenomics Testing Among Physicians, Pharmacists, and Researchers From China
por: Guo, Chengxian, et al.
Publicado: (2021)

Comprehensive Evaluation of Organotypic and Microphysiological Liver Models for Prediction of Drug-Induced Liver Injury
por: Zhou, Yitian, et al.
Publicado: (2019)

Molecular Biomarkers in Drug-Induced Liver Injury: Challenges and Future Perspectives
por: Fu, Siyu, et al.
Publicado: (2020)

Drug-induced kidney injury in Chinese critically ill pediatric patients
por: Hu, Biwen, et al.
Publicado: (2022)

Whole genome sequencing in pharmacogenomics
por: Katsila, Theodora, et al.
Publicado: (2015)

Pharmacogenomics of Prostaglandin and Leukotriene Receptors
por: Cornejo-García, José A., et al.
Publicado: (2016)

Ethnic Diversity and Warfarin Pharmacogenomics
por: Asiimwe, Innocent G., et al.
Publicado: (2022)

Editorial: Pharmacogenomics in neglected populations
por: Botton, Mariana R., et al.
Publicado: (2022)

Pharmacogenomics in clinical trials: an overview
por: Nogueiras-Álvarez, Rita
Publicado: (2023)

Clinical practice guidelines for translating pharmacogenomic knowledge to bedside. Focus on anticancer drugs
por: Agúndez, José A. G., et al.
Publicado: (2014)

Drug-Induced Severe Cutaneous Adverse Reactions: Insights Into Clinical Presentation, Immunopathogenesis, Diagnostic Methods, Treatment, and Pharmacogenomics
por: Tempark, Therdpong, et al.
Publicado: (2022)

The Characteristics, Prevalence, and Risk Factors of Drug-Induced Liver Injury Among Brucellosis Inpatients in Xinjiang, China
por: Tuohutaerbieke, Maermaer, et al.
Publicado: (2021)

Correlation between serum cytokines and clinicopathological features in patients with drug-induced liver injury
por: Zhang, Yu, et al.
Publicado: (2022)

Targeting cancer-related inflammation with non-steroidal anti-inflammatory drugs: Perspectives in pharmacogenomics
por: Lai, Hongjin, et al.
Publicado: (2022)

Pharmacogenomics of human P450 oxidoreductase
por: Pandey, Amit V., et al.
Publicado: (2014)

Current clinical evidence on pioglitazone pharmacogenomics
por: Kawaguchi-Suzuki, Marina, et al.
Publicado: (2013)

Editorial: Insights in Pharmacogenetics and Pharmacogenomics: 2021
por: Agúndez, José A. G., et al.
Publicado: (2022)

Pharmacogenomics at the post-pandemic: If not now, then when?
por: Al-Mahayri, Zeina N.
Publicado: (2022)

The pharmacogenomic landscape of an Indigenous Australian population
por: Samarasinghe, Sumudu Rangika, et al.
Publicado: (2023)

Pharmacogenomics of Medications Commonly Used in the Intensive Care Unit
por: Zhou, Shuqin, et al.
Publicado: (2018)

Pharmacotherapies for Drug-Induced Liver Injury: A Current Literature Review
por: Li, Meng, et al.
Publicado: (2022)

Metabolomic Profiling for Histologically Fibrotic Stage in Chronic Drug-Induced Liver Injury
por: He, Xian, et al.
Publicado: (2022)

Drug-Induced Liver Injury: Biomarkers, Requirements, Candidates, and Validation
por: Meunier, Lucy, et al.
Publicado: (2019)

Chronic Drug-Induced Liver Injury: Updates and Future Challenges
por: Wang, Qiaoling, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_b4g1lquginua8di4apmjarqiqa